Evidence map›Paper›PMID 29196796›Full record

ArticleImmunogenetics2018

Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.

Pieter Meysman, Nicolas De Neuter, Esther Bartholomeus, George Elias, Johan Van den Bergh, Marie-Paule Emonds, Geert W Haasnoot, Steven Heynderickx, Johan Wens, Nele R Michels and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunogenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 4 countries.

Pieter MeysmanADREM Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2020, Antwerp, Belgium. pieter.meysman@uantwerpen.be.ORCID http://orcid.org/0000-0001-5903-633X
Nicolas De NeuterADREM Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2020, Antwerp, Belgium.
Esther BartholomeusAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
George EliasAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
Johan Van den BerghLaboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650, Antwerp, Belgium.
Marie-Paule EmondsLaboratory for Histocompatibility and Immunogenetics (HILA), Red Cross Flanders, 2800, Mechelen, Belgium.
Geert W HaasnootDepartment of Immunohaematology and Blood Transfusion, Leiden University Medical Center, 2300, Leiden, The Netherlands.
Steven HeynderickxLaboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650, Antwerp, Belgium.
Johan WensDepartment of Primary and Interdisciplinary Care, University of Antwerp, 2610, Wilrijk, Belgium.
Nele R MichelsDepartment of Primary and Interdisciplinary Care, University of Antwerp, 2610, Wilrijk, Belgium.
Julien LambertDepartment of Dermatology, Antwerp University Hospital/University of Antwerp, 2650, Edegem, Belgium.
Eva LionLaboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650, Antwerp, Belgium.
Frans H J ClaasDepartment of Immunohaematology and Blood Transfusion, Leiden University Medical Center, 2300, Leiden, The Netherlands.
Herman GoossensDepartment of Laboratory Medicine, Antwerp University Hospital, 2650, Edegem, Belgium.
Evelien SmitsAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
Pierre Van DammeCentre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2610, Antwerp, Belgium.
Viggo Van TendelooAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
Philippe BeutelsAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
Arvid SulsAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
Geert MortierAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
Kris LaukensADREM Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2020, Antwerp, Belgium.
Benson OgunjimiAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
University of Antwerp · BELeiden University Medical Center · NLAntwerp University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Around 30% of individuals will develop herpes zoster (HZ), caused by the varicella zoster virus (VZV), during their life. While several risk factors for HZ, such as immunosuppressive therapy, are well known, the genetic and molecular components that determine the risk of otherwise healthy individuals to develop HZ are still poorly understood. We created a computational model for the Human Leukocyte Antigen (HLA-A, -B, and -C) presentation capacity of peptides derived from the VZV Immediate Early 62 (IE62) protein. This model could then be applied to a HZ cohort with known HLA molecules. We found that HLA-A molecules with poor VZV IE62 presentation capabilities were more common in a cohort of 50 individuals with a history of HZ compared to a nationwide control group, which equated to a HZ risk increase of 60%. This tendency was most pronounced for cases of HZ at a young age, where other risk factors are less prevalent. These findings provide new molecular insights into the development of HZ and reveal a genetic predisposition in those individuals most at risk to develop HZ.

Indexed as

AdultAgedBelgiumChickenpoxFemaleGenetic Predisposition to DiseaseHerpesvirus 3, HumanHerpes ZosterHLA-A AntigensHumansImmediate-Early ProteinsMaleMiddle AgedModels, ImmunologicalRisk FactorsTrans-ActivatorsHLA-A AntigensIE62 protein, Human herpesvirus 3Immediate-Early ProteinsTrans-ActivatorsViral Envelope ProteinsHerpes zosterHLA associationMHC peptide affinityVaricella zoster virus

Identifiers

PMID29196796
OpenAlexW2772254682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.